EGFR and non-small cell lung carcinoma: In a population-based study using multicenter, nationwide electronic health record-derived data from the Flatiron database, Robinson et al. reported that among patients with advanced EGFR-mutated NSCLC between 2016 and 2022 whose disease progressed on 1L osimertinib (22.7%), 37% (197/538) received ICI-containing treatment in the 2L setting [17].